Merck KGaA: Surprising decision to move tecemotide forward in phase III
NEUTRAL, Fair Value EUR110 (-4%)
Time will tell if Merck is right to keep investing in its investigational therapeutic vaccine tecemotide (last known as Stimuvax) whose phase III START failed to show an OS benefit when results were unveiled earlier this year. From the very beginning it was said that although the trial failed to reach its primary endpoint, subgroups did show a benefit with the drug.
Full report available to subscribers
Please contact firstname.lastname@example.org